CG Oncology, Inc. $CGON Shares Bought by Clearbridge Investments LLC

Clearbridge Investments LLC raised its position in CG Oncology, Inc. (NASDAQ:CGON) by 14.9% during the 4th quarter, Holdings Channel reports. The firm owned 705,014 shares of the company’s stock after acquiring an additional 91,162 shares during the quarter. Clearbridge Investments LLC’s holdings in CG Oncology were worth $29,272,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CGON. AQR Capital Management LLC acquired a new stake in CG Oncology in the first quarter valued at $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of CG Oncology by 18.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after acquiring an additional 5,442 shares during the last quarter. Millennium Management LLC boosted its stake in shares of CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after acquiring an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of CG Oncology by 42.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after acquiring an additional 53,461 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of CG Oncology by 12.3% during the second quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after acquiring an additional 4,847 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analyst Ratings Changes

CGON has been the topic of a number of analyst reports. Royal Bank Of Canada increased their price objective on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Wedbush increased their price objective on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Truist Financial reaffirmed a “buy” rating and set a $82.00 price objective (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $81.73.

CG Oncology Trading Up 4.2%

Shares of NASDAQ:CGON opened at $56.67 on Wednesday. The stock’s 50-day moving average price is $65.57 and its two-hundred day moving average price is $56.31. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $75.50. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of -24.32 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, research analysts forecast that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Transactions at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $54.50, for a total value of $54,500.00. Following the sale, the director directly owned 1,000 shares of the company’s stock, valued at approximately $54,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James Mulay sold 15,600 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the sale, the director directly owned 15,600 shares in the company, valued at approximately $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 18,564 shares of company stock worth $1,318,170. 4.80% of the stock is owned by corporate insiders.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.